Rare cause of Hemophagocytic Lymphohistiocytosis due to mutation in PRF1 and SH2D1A genes in two children – a case report with a review

Jayesh Sheth1*, Akash Patel1, Raju Shah2, Riddhi Bhavsar1, Sunil Trivedi1 and Frenny Sheth1

Abstract

Background: Hemophagocytic Lymphohistiocytosis (HLH) is a rare, complex, life-threatening hyper-inflammatory condition due to over activation of lymphocytes mediated secretory cytokines in the body. It occurs as a primary HLH due to genetic defect that mostly occurs in the childhood and associated with early neonatal death. Secondary HLH is triggered by secondary to infection and can occur at any age.

Case presentation: The current report presents two cases of HLH. Case 1, three-months-old boy born to second degree consanguineous parents was clinically suspected with HLH. A pathogenic variant in exon 2 of PRF1 gene [c.386G > C (p.Trp129Ser); FLH-type2] was detected. The parents and the fetus under investigation were shown to be heterozygous carriers, while Case-1 was homozygous for the said variant. Case 2, a one and half-year old male child referred for work-up was born to non-consanguineous young parents. His HLH suspicion was in accordance with HLH-2004 Revised diagnostic guidelines (fulfilling 5/8 criteria). Molecular study revealed hemizygous likely pathogenic variant c.138-3C > G in intron 1 of SH2D1A gene. Both the mother and younger sister were confirmed to be the carrier of the same variant.

Conclusion: This study has represented two rare cases of HLH carrying missense variant in PRF1 and splice site variant in SH2D1A gene. Detailed molecular analysis has helped the families with precise genetic counselling and prenatal diagnosis during subsequent pregnancy. It is advocated that male patients presenting with EBV-associated HLH may be screened for XLP that may lead to early diagnosis and therapeutic implication if any.

Keywords: Case report, Hemophagocytic Lymphohistiocytosis, HLH, PRF1, SH2D1A, Next generation sequencing, Carrier status

Background

Hemophagocytic Lymphohistiocytosis (HLH) is a rare, complex and life-threatening syndrome which is characterized by hyper-inflammation due to over-activation of lymphocytes that releases secretory cytokines in the body [1]. The actual epidemiology of HLH is difficult; however, overall estimated prevalence of HLH in patients younger than 18 years from different ethnic groups is approximately 1 per 100,000 [2]. HLH is classified in two groups, primary or genetic form (P-HLH) where genetic defect is an underlying cause. P-HLH is normally inherited in an autosomal recessive pattern and mostly observed in childhood leading to early death. Secondary or acquired HLH is triggered due to viral infection, autoimmune/rheumatologic, malignant or metabolic conditions and is seen across all age groups [3].

Primary-HLH is further classified in two groups; Familial HLH (FHL) and Lymphoproliferative disorder [4]. Worldwide incidence of FHL is not known. However, extensive studies on FHL are carried out in Sweden and are shown to occur at an estimated incidence of 1 in 50,000 live births [5]. FHL syndromes are sub-classified...
into FHL-1 through FHL-5, depending upon the gene/s involved and alterations in the functional protein. FHL has an autosomal recessive inheritance and is more commonly seen in the consanguineous families [6, 7]. The prominent feature of hemophagocytosis is seen during early disease course. It very rarely occurs in secondary HLH or might be observed late after the disease has progressed [1].

The diagnosis of primary and/or secondary HLH is carried out – either on clinical presentations or molecular findings or both as suggested by the Histiocyte Society [8]. Nearly 58% FHL cases are reported to harbour mutations in PRF1 gene (located at 10q22.1) that alters the normal function of perforin [8]; whereas 40–60% of all X-linked lymphoproliferative disorders harbour mutation in SLAM-associated protein (SAP) regulating gene SH2D1A (located at Xq25) [9]. One hundred eight disease-causing mutations in the PRF1 gene and 99 disease causing mutations in the SH2D1A gene have been reported so far in the literature [10, 11] including 14 HLH cases from India attributed to mutations in the PRF1 gene [12–14]. We report here two cases of HLH with the mutation in PRF1 and SH2D1A gene each.

To the best of our knowledge the molecular studies on mutation in SH2D1A gene is reported for the first time from India. Both the cases were enrolled for the study as per the institutional ethics committee guidelines in accordance with Helsinki declaration.

**Case presentation**

**Case 1**

A young second degree consanguineous parents Fig 1 were referred for genetic counselling during third gravida as their second child (P1) expired at the age of 3 months due to hepatomegaly with pancytopenia. Proband’s elder sister was normal. The proband was born at full term with a birth weight of 3.3 kg. The neonatal period was uneventful. At the age of 3 months, he presented with chief complains of high grade intermittent fever, excessive crying, irritability and reduced oral intake for three days. General examination showed tachycardia and tachypnea. On abdominal examination, the liver was palpable by 4 cms in midclavicular line, firm and nodular in consistency. Haematological examination showed pancytopenia (haemoglobin: 9.5g/dl, Leukopenia: 4660 WBC/cmm, platelets count 55,000/cmm). Biochemical parameters were elevated [serum ALT: 456 U/l, AST: 2348 U/l, ferritin (3994 ng/ml), triglycerides (222 mg/dl), prothrombin time (PT) 22 s and activated partial thromboplastin time (APTT) 50 s]. Serum fibrinogen was decreased (120 mg/dl). Ultrasonography revealed hepatomegaly, mild right pleural effusion, and mild sub-hepatic fluid collection. Bone marrow examination revealed cellular marrow with reactive changes. Based on this, the proband was clinically suspected for HLH.

The genomic DNA was isolated from peripheral blood [15] and processed for Hemophagocytic Lymphohistiocytosis gene panel on Hisseq-Illumina NGS platform. A homozygous mutant variant c.386G>C (p.Trp129Ser) in exon-2 of PRF1 gene (OMIM* 170280; NM_005041.5; NP_001076585.1) on chromosome 10q22.1 was detected as shown in Fig. 2. This variant causes substitution of Serine on Tryptophan at codon 129 (ENSP00000398568). In-silico analysis tools like mutation tester, SIFT, Polyphen2 predicted the damaging effect of the said variant. This variant is not reported in the 1000 genome database and found to be damaging (rs768849283). Bidirectional Sanger sequencing further confirmed parents to be heterozygous for the same variant [c.386G > C (p.Trp129Ser) in exon 2 of PRF1 gene] [Additional file 1]. All these investigations confirmed the autosomal recessive inheritance of FHL2. Prenatal diagnosis from chorionic villus (CVS) was carried out at 12 weeks of gestation which has revealed heterozygous status for c.386G>C variant in exon 2 of PRF1 gene. A normal carrier child was delivered at full term normal delivery.

**Case-2**

The male child (P2; 5th gravida) was born at full-term with a birth weight of 2.25 kg. The postnatal period was uneventful. He was born of non-consanguineous young parents Fig. 3. Earlier, the eldest brother of the proband died at an age of 4 days due to prematurity. The second brother died at the age of 3 years with similar complains as of the index case and had two healthy elder normal sisters (aged 14 years and 11 years). Both the brothers of proband’s mother died earlier at an age of 3 years due to high ALT (330 IU/ml) and lactic acid levels. The proband was referred with the chief complain of persistent fever (15 days’ duration) at the age of 16 months and had one episode of focal seizure with twitching over the face (which lasted for 2–3 min) that subsided on its own
within 3 days. At the age of 17 months, the proband was admitted to the hospital due to viral illness. The physical examination revealed a mild oedematous face. Upon abdominal examination, the liver was palpable by 3 cm in midclavicular line, firm and nodular in consistency. The spleen was 2+ cm palpable towards umbilicus, firm and nodular in consistency. There was no facial dysmorphism observed.

Haematological investigation revealed peripheral blood with pancytopenia (haemoglobin: 6.9 g/dl, Leukopenia:
WBC 2570/cmm, decreased platelets count 3000/cmm). Biochemical parameters were elevated [serum ALT: 300 U/l, prothrombin time (PT) 20 s and activated partial thromboplastin time (aPTT) 58 s]. Cerebrospinal fluid examination was performed due to the history of fever and convulsion and was suggestive of aseptic Meningitis as mentioned in the clinical note. EBV was tested positive by serologic testing. Bone marrow examination revealed cellular marrow aspirate with adequate erythropoiesis, myeloid hyperplasia, toxic changes, and a moderate increase in reticulum fibers, mild eosinophilia and adequate megakaryocyte suggestive of reactive marrow changes. However, there was an evidence of hemophagocytosis on trephine bone marrow biopsy. Ultrasonography revealed mild splenomegaly, moderate hepatomegaly and minimal free fluid in the peritoneal cavity; kidneys, pancreas, gall bladder, and para-aortic region were unremarkable. MRI of the brain was suggestive of meningoencephalitis with post-infective extensive demyelination in all lobes (fronto-temporal-parito-occipital), bilateral involvement of periventricular white matter, basal ganglia, thalamus, brain stem, and cerebellar hemisphere; no fresh infarct, Space-Occupying Lesion (SOL), haemorrhage, a malformation in brain parenchyma Fig. 4. Biochemical studies were performed that ruled out Gaucher and Niemen-Pick–A disease. β-Glucosidase, plasma Chitotriosidase, Acid Sphingomyelinase were also normal. In view of pyrexia of unknown origin (PUO), hepatosplenomegaly, pancytopenia, hypertriglyceridemia, high ferritin and hemophagocytosis, HLH was suspected and clinically confirmed in accordance with Henter-2004 revised diagnostic guidelines (5/8 criteria). The proband died at the age of 19 months due to meningoencephalitis.

Further confirmation of the diagnosis was made by isolation of genomic DNA from peripheral blood [15] that was subjected to clinical exome sequencing on Miseq-Illumina NGS platform which has identified a hemizygous likely pathogenic variant c.138-3C>G in the intron-1 of SH2D1A gene (OMIM*300490; NP_002342.1; NM_002351.4; Fig. 5). In-silico prediction tool (ASSP) further support the effect of this variant affect the splice site of exon-2 and causes frameshift termination (p.Arg47GlyfsTer34) of the protein (80 amino acid residues instead of 128 amino acid residues). Mutation Taster suggested the variant to be disease-causing. This variant was not found either in ExAC or 1000 Genome Databases. Bidirectional Sanger sequencing was performed to validate its presence (Additional file 1). Mother and the younger sister of the proband were investigated and found to be heterozygous for c.138-3C>G mutation in intron-1 of SH2D1A gene.

Discussion and conclusion

Literature survey for mutations in exon-2 of PRF1 and intron-1 of SH2D1A genes are presented in Additional file 2. PRF gene mutations (N = 33/108; Additional file 2) span over multiple ethnicities [10]. They are mostly observed in Asian and European population and less commonly seen in American and other populations [10, 11]. Nonsense mutation (p.Trp34Ter) is mostly seen in Turkish population [16, 17], frameshift mutation (c.1090_1091delCT and c.50delT) is more commonly observed in Japanese and African-American population [17, 18] whereas missense mutation (p.Ala91Val and p.Trp129Ser) is seen in Italian and Indian population respectively [12, 13, 19]. Most of the missense mutations commonly seen in HLH are observed under the umbrella of PRF1 gene. Nonetheless,
such ethnic predilection is not reported for SH2D1A gene mutation [11].

In our study, proband P1 has shown to have aforesaid disease-causing mutation (p.Trp129Ser) in PRF1 gene. This gene encodes for perforin protein, located at 10q22.1 region and is obligatory for granule release mechanism of Natural Killer cells (NK-cell) and cytotoxic T lymphocytes (CTL) by forming pores into plasma membrane of the target cells and for passive diffusion of granzyme B for an apoptotic event [13]. This protein is expressed up to 0–3% on CD8+ cells in the children from birth till 1 year of age whereas it is expressed on CD56+ cells from 1 to 30% in lymphocytes from 1 year to 15 years of age [18]. In our case P1, missense mutation p.Trp129Ser in PRF1 gene is likely to have caused a gain in glycosylation site of protein structure that result in loss of the binding stability with intracellular calcium ions [21]. This renders perforin protein to become non-functional through changes in conformation leading to defective NK cell activity which has been observed in the majority of FHL patients [12–22]. Though present study lacks the functional evidence of defective NK cell activity, Schneider et al. have classified FHL patients into four sub-types. This indicates that PRF1 mutation is likely to play an important role in the persistence of deficient NK cell activity in FHL cases [24].

Katano et al. had demonstrated accumulation of an uncleared precursor form of perforin and absence of an active mature form of perforin in patients with PRF1 missense mutation [25]. This indicates that missense mutation of PRF1 gene causes conformational changes in the protein and inhibits the proteolytic cleavage of perforin precursor. The immune competence of patients with FHL depends on functional analysis of antigen-specific cytotoxic T-lymphocytes (CTLs). Cytotoxic formation in patient with missense mutation in PRF1 gene remains intact than those having nonsense mutation [24]. Nonetheless, functional analysis of antigen-specific CTLs may yield better insight into the immune competence of patients.

In proband P2, disease-causing hemizygous variant (c.138-3C>G) in intron-1 of SH2D1A gene was detected. The same variant was reported earlier by Sayos et al. in a 6-year-old Italian boy [26]. This gene encodes SAP protein, located on Xq25 position [9]. It has a role as a key regulator in normal immune function of all three; NK-T (Natural killer T) cells, T-cells and B-cells. Increased SAP expression is seen in thymus-derived lymphocytes. A SLAM-SAP interaction initiates the lymphocyte activation [26, 27]. Variant c.138-3C>G affects the splice site of
et al. [29] suggested that altered function of a 2B4 molecule cell-mediated cytotoxicity. The model proposed by Parolini to be due to defect in NK cell activation and NK lymphocytes by defective Helper T cells [28] which is likely EBV infection, due to an elimination of EBV-infected B wards a failure of immune system in protecting against early diagnosis and therapeutic implication if any.  

A positive Epstein Barr virus test in the proband point to- wards a failure of immune system in protecting against EBV infection, due to an elimination of EBV-infected B lymphocytes by defective Helper T cells [28] which is likely to be due to defect in NK cell activation and NK cell-mediated cytoxicity. The model proposed by Parolini et al. [29] suggested that altered function of a 2B4 molecule (SLAM family member) affects the ability to control EBV infection in the body. The authors also showed that in the absence of SAP/2B4-mediated recognition, CD48 play a crucial role in the inhibition of NK cell-mediated killing of EBV-infected B-cell. Benoit et al. [30] also suggested that SAP/2B4 signal alteration leads to immune dysfunction. Immune system failure in the killing of EBV-Infected cells leads to prolonged activation of cytotoxic cells and results in cytokine secretion which activates macrophages. It decreases blood cell count and haemoglobin level which leads to hemophagocytosis in bone marrow and deranged liver functions which has been observed in the case under report. This indicates that the gene variant affects the immune function but after the viral infection, XLP becomes life-threatening as seen in the present case.  

XLP1 patients with splice site variants are reported to have two years average median age of onset and predicted survival of 3 years [31] which is in accordance with our observation. This indicates that lack of SAP resulting as a consequence of variants leads to a severe activation of lymphocytes and have a profound effect on the patients. It was also noted that XLP patients who have a nonsense and deletion mutations have a decreased SAP whereas missense and splice site mutations have absent or decreased SAP expression [9].  

The patients who are either not treated with specific therapies or undergoing transplantation die mostly due to severe pancytopenia that deregulates immune function. Moreover, it is reported that with fungal, bacterial or viral infection the survival of patients without treatment is < 2 months [32] as seen in both these cases.  

In conclusion, our study reports mutation in PRF1 and SH2D1A gene respectively that are known to be associated with HLH. Detailed molecular analysis has helped the families with precise genetic counselling and prenatal diagnosis during subsequent pregnancy. It is also recommended that male patients presenting with EBV-associated HLH need to be screened for XLP for early diagnosis and therapeutic implication if any.  

Additional files

**Additional file 1:** Protocol for Sanger sequencing. (DOCX 14 kb)

**Additional file 2:** Genotype and phenotype variation in some reported cases of SH2D1A and PRF1 genes. (DOCX 27 kb)

Abbreviations

- aPTT: Activated partial thromboplastin time
- CD: Cluster of Differentiation
- CNS: Central nervous system
- CSF: Cerebrospinal fluid
- EBV: Epstein - Barr virus
- ExAC: The Exome Aggregation Consortium
- FHL: Familial Hemophagocytic Lymphohistiocytosis
- HLH: Hemophagocytic Lymphohistiocytosis
- IL2Rα: Interleukin 2 receptor α
- MRI: Magnetic resonance imaging
- NGS: Next-Generation sequencing
- NK: Natural killer
- NK-T cell: Natural killer-T cell
- OMMI: Online mendelian inheritance in men
- PRF1: Perforin1
- SOL: Space-Occupying Lesion
- WBC: White blood cells
- SH2D1A: SH2 Domain 1A
- SIFT: Scale-Invariant feature transform
- SLAM: Signaling lymphocyte activation molecule
- SOL: Space-Occupying Lesion
- WBC: White blood cells

Acknowledgments

We thank Dr. Kunjal Patel for his partial help in the clinical note for the manuscript. We thank Dr. Suresh Kuppanan and Ms. Dhanya Pancholi for suggestions. We express our thanks to patients and their families for their support.

Funding

No funding has been received from any agencies.

Availability of data and materials

The dataset is generated and/or analysed during the current study is available in the ClinVar repository c.386G>C (p.Trp129Ser) variant in Exon-2 of PRF1 gene https://www.ncbi.nlm.nih.gov/clinvar/variation/548929/#clinical-assertions ClinVar accession ID:-SCV000778446.1 and c.138-3C > G variant in Intron-1 of SH2D1A gene https://www.ncbi.nlm.nih.gov/clinvar/variation/548931/#clinical-assertions ClinVar accession ID:-SCV000778445.1.

Authors contribution

JS, RB and FS have standardized protocol and designed the experiment. Clinical Details prepared by JS, FS and RS. RB and AP involved in sample processing. JS, FS, ST and AP prepared the manuscript. All the authors read and approved the final manuscript.

Ethics approval and consent to participate

The present case report has been approved by the institutional ethics committee [FRIGE’s Institute of Human Genetics] with approval number FRIGE/IEC/14/2016 dated 19th November 2016. This process is in accordance with Helsinki declaration.

- An informed consent for investigation and publication was obtained from the probands’ legal guardians at the time of enrolment for the study [This was in accordance with the requirement of the institutional ethics committee].
- Informed written consent was obtained from all study participants [parents (adults), legal guardians (parents) consented on behalf of their minor children].

Consent for publication

Informed written consent was obtained from all study participants [parents (adults), legal guardians (parents) consented on behalf of their minor children], for genetic testing, inclusion in the study and as publication of their clinical details and/or clinical images. A copy of the written consent is available for review.

Competing interests

The authors declare that they have no competing interest (financial or non-financial) in the present study.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1FRIGE Institute of Human Genetics, FRIGE House, Jodhpur Garm Road, Satellite, Ahmedabad, Gujarat 380015, India. 2Ankur Institute of Child Health, Behind City Gold Cinema, Ashram Road, Navrangpura, Ahmedabad, Gujarat 380009, India.

Received: 9 November 2018 Accepted: 26 February 2019

Published online: 08 March 2019

References
1. George MR. Hemophagocytic lymphohistiocytosis: review of etiologies and management. Journal of Blood Medicine. 2014;5:69–86.
2. Niece JA, Rogers ZR, Ahmad N, Langevin AM, McClain KL. Hemophagocytic lymphohistiocytosis in Texas: observations on ethnicity and race. Pediatr Blood Cancer. 2010;54:424–8.
3. Madkaikar M, Shabirsh S, Desai M. Current updates on classification, diagnosis and treatment of Hemophagocytic Lymphohistiocytosis (HLH). Indian J Pediatr. 2016;83:434–43.
4. Waleed A, Bousthina A, Casonova JL, Chatila T, Conley ME, Cunningham-Rundles C, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for primary immunodeficiency. Front Immunol. 2014;22:162. https://doi.org/10.3389/fimmu.2014.00162.
5. Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 1991;80:428–35.
6. Mehta RS, Smith ER. Hemophagocytic lymphohistiocytosis (HLH): a review of literature. Med Oncol. 2013;30:7-40.
7. Ericson KG, Fadeel B, Soderhall C, Samuelsson A, Janka G, et al. Spectrum of perforin gene mutations in familial Hemophagocytic Lymphohistiocytosis. Am J Hum Genet. 2001;68:590–7.
8. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imausu S, et al. HLH-2004: diagnostics and therapeutic guidelines for Hemophagocytic Lymphohistiocytosis. Pediatr Blood Cancer. 2006;48:214–31.
9. Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndrome: brothers or distant cousins? Blood. 2010;116:398–408.
10. HGMD Database. http://www.hgmd.cf.ac.uk/ac/index.php?gene=PRF1 Accessed 14 sept 2018.
11. HGMD Database. http://www.hgmd.cf.ac.uk/ac/index.php?gene=SH2D1A Accessed 14 sept 2018.
12. Mhatre S, Madkaikar M, Jianna F, Ghosh K. Unusual clinical presentation of familial Hemophagocytic Lymphohistiocytosis Type-2. JPediatrHematol Oncol. 2014;36:e524–7.
13. Mhatre S, Madkaikar M, Desai M, Ghosh K. Spectrum of perforin gene mutation in familial lymphohistiocytosis (FHL) patients in India. Blood cells Mol Disease. 2015;54:250–7.
14. Madkaikar M, Gupta M, Dixit A, Patil V. Predominant neurologic manifestations seen in a patient with a Biallelic Perforin1 mutation (PRF1; p. R225W). J Pediatr Hematol Oncol. 2017;39:143–6.
15. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
16. Zur Stadt BK, Kolberg K, Schneppenheim R, Kabisch H, Janka G, et al. Mutation Spectrum in children with primary Hemophagocytic Lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D,STX11, and RAB27A. Hum Mutat. 2006;27:62–8.
17. Clemente R, Emini L, Maccario R, Irotta F, Moretta L, Danesino C, et al. Adult onset and atypical presentation of hemophagocytic lymphohistiocytosis in X-linked lymphoproliferative disease. Mol Immunol. 2002;39:2266–7.
18. Chia J, Thia K, Brennan AJ, Little M, Williams B, Lopez JA, et al. Fatal immune dysregulation due to gain of glycosylation mutation in lymphocyte perofrin. Blood. 2012;119:1713–6.
19. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002;99:61–66.
20. Feldmann J, Dietl F, Ouache e-Charlin M, Certain S, Sarah A, Quartert P, et al. Functional consequences of perforin gene mutations in 22 patients with familial haemophagocytic lymphohistiocytosis. Br J Haematol. 2002;117:965–72.
21. Schneider EM, Lorenz I, Muller-Rosenberger M, Steinbach G, Krom M, Janka-Schaub GE. Hemophagocytic lymphohistiocytosis (HLH) is associated with deficiencies of cellular cytolysis but normal expression of apoptosis related transcripts. Blood. 2002;100:2891–8.
22. Ishii E, Ueda I, Shitakawa R, Yamamoto K, Horuchi H, Ohga S, et al. Genetic subtype of familial hemophagocytic lymphohistiocytosis: correlations with clinical features and cytotoxic T lymphocytes/natural killer cell function. Blood. 2005;105:3442–9.
23. Katano H, Ali MA, Patera AC, Catalafamo M, Jaffe ES, Kimura H, et al. Chronic active Epstein-Barr virus infection associated with mutations in perforin that impair its maturation. Blood. 2003;103:1244–52.
24. Sayas J, Wu C, Morra M, Wang N, Zhang X, Allen D, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signal induced through the co-receptor SLAM. Nature. 1998;395:462–9.
25. Nichols KE, Ma CS, Cannons JL, Schwartzberg PL, Tangye SG. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev. 2005;203:180–99.
26. Sumegi J, Seenayyer TA, Huang D, Davis JR, Morra M, Gross TG, et al. A spectrum of mutations in SH2D1A that causes X-linked lymphoproliferative disease and other Epstein-Barr virus-associated illnesses. Leuk Lymphoma. 2002;43:1189–01.
27. Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, Franceschini R, et al. X-linked lymphoproliferative disease: 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus infected cells. J Exp Med. 2000;192:337–46.
28. Benoit L., Wang X., Pabst H.F., Dutz, J, Tan R. Defective NK cell activation in X-linked lymphoproliferative disease. J Immunol. 2000;165:3549–53.
29. Parolini S, Bottino C, Falco M, Augugliaro R, Giliani S, Franceschini R, et al. X-linked lymphoproliferative disease. J Immunol. 2000;165:3549–53.
30. Sumegi J, Huang D, Lanyi A, Davis JD, Seenayyer TA, Maeda A, et al. Correlation of mutation of SH2D1A gene and Epstein-Barr virus mutation with clinical phenotypes and outcome in X-linked lymphoproliferative disease. Blood. 2000;96:1318–25.
31. Janka GE. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr. 1983;140:221–30.